Timothy Izzo, DO
Family Medicine · Grand Ledge, MINPI 1720152846
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,000 of the $124,093 with a category attached, or 72.5%. Lilly USA, LLC accounts for 91.1% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2023 at $50,117 and has fallen 90.5% since, to $4,748 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,211 payments — averaging $102.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$113K
- Novo Nordisk$2K
- AbbVie$2K
- Pfizer$1K
- Amgen$988
- GSK$804
- plus $5K from 44 others
What the payments were for
- Consulting fees$8,0006%
- Speaking & faculty fees$90,00073%
- Travel & lodging$10,2848%
- Food & beverage$15,76013%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,093 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 253 | $347,945 |
| EliquisApixaban | 177 | $237,512 |
| JardianceEmpagliflozin | 121 | $178,900 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $80,679 |
| XareltoRivaroxaban | 52 | $68,956 |
| TrulicityDulaglutide | 26 | $60,358 |
| NuplazidPimavanserin Tartrate | 12 | $60,084 |
| JanuviaSitagliptin Phosphate | 38 | $59,720 |
| MyrbetriqMirabegron | 54 | $55,239 |
| OzempicSemaglutide | 29 | $53,598 |
| ProliaDenosumab | 31 | $52,702 |
| FarxigaDapagliflozin Propanediol | 37 | $48,164 |
| Teriparatide | 11 | $44,134 |
| Wellbutrin XlBupropion Hcl | 17 | $41,135 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $34,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $113,074 | $408,303279 claims |
| PfizerEliquis | $1,070 | $237,512177 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $479 | $188,826138 claims |
| MerckJanuvia, Janumet | $252 | $94,14161 claims |
| Novo NordiskOzempic, Rybelsus | $1,775 | $84,38941 claims |
| GSKTrelegy Ellipta | $804 | $80,67960 claims |
| Johnson & JohnsonXarelto | $453 | $68,95652 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $55,23954 claims |
| AmgenProlia | $988 | $52,70231 claims |
| AstraZenecaFarxiga | $493 | $48,16437 claims |
| AbbVieLinzess | $1,639 | $18,81714 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $60 | $10,99413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Grand Ledge
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Oren MasonGrand Rapids$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.